Two studies have demonstrated that there is no difference in the genotype frequency of GPX1 Pro198Leu polymorphism between prostate cancer patients and healthy controls or between aggressive and non-aggressive prostate cancer patients in the Turkish population [60,61]. Here, GPX1 is linked to prostate carcinoma.